{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33499"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33499","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Longitudinal Health-Related Quality of Life in Adult High Grade Glioma Patients: A Single Centre Observational Database","abstract":"Introduction: Intracranial high-grade glioma (HGG) is an aggressive intra-axial brain malignancy with unfortunately poor prognosis. Increasing survival is a major focus of current research, with much less emphasis on the quality of life that patients have remaining. The existing data focuses on single moments in the disease process, primarily assessing the impact of one treatment factor on health-related quality of life (HRQOL). Many studies do not use direct, validated measures of HRQOL specific to patients with HGG. The objective of this study is to create a comprehensive database of HGG patients including validated, disease-specific measures of HRQOL to explore longitudinal trends in HRQOL throughout the disease journey. Methods: An observational, prospective database encompassing all newly-diagnosed, pathology-confirmed adult HGG patients treated in Hamilton, Ontario was developed. Demographic and clinical data was broadly collected. HRQOL questionnaires including the FACT-Br and EORTC-QLQ BN20 were administered at various timepoints up to 1 year following surgery. Longitudinal changes in HRQOL were analyzed using linear mixed-effects models. All analyses were completed using IBM SPSS Statistics for MacIntosh (Version 29.0, IBM Corp 2023), with a significance level of p <0.05. Results: The total number of participants in the cohort was n=65. Survey response rates ranged from 45%-100% for each follow-up timepoint. Linear mixed-effects modelling demonstrated a significant influence of time on EORTC-QLQ BN-20 (p<0.001). Estimated marginal mean scores increased from 23.1 at baseline to 47.2 at 12 months, indicating worsening HRQOL at 12 months. FACT-Br total scores showed no significant difference over time (p = 0.754). Regarding the HRQOL subscales, there was a significant influence of time on social well-being (p=0.032), though not in physical, emotional, or functional subscales (all p>0.10). Conclusion: This thesis provides information regarding longitudinal trends in HRQOL in HGG. Namely, we found that during treatment stages, HRQOL remains relatively stable, with a slight decrease in social functioning. Immediately following the treatment stages, HRQOL may slightly improve before declining towards disease progression and/or end of life. Limitations of this study include the small sample size (particularly at later time points), possible bias of results towards better-functioning individuals, and poor representation of end-of-life due to patient withdrawal at this stage. HRQOL research in HGG is a challenging endeavour which requires substantial multidisciplinary support to develop meaningful results. Nonetheless, it is a meaningful and important topic that requires greater attention to encourage multidisciplinary and holistic support of HGG patients throughout their illness journey.","abstract_html":"Introduction: Intracranial high-grade glioma (HGG) is an aggressive intra-axial brain malignancy with unfortunately poor prognosis. Increasing survival is a major focus of current research, with much less emphasis on the quality of life that patients have remaining. The existing data focuses on single moments in the disease process, primarily assessing the impact of one treatment factor on health-related quality of life (HRQOL). Many studies do not use direct, validated measures of HRQOL specific to patients with HGG. The objective of this study is to create a comprehensive database of HGG patients including validated, disease-specific measures of HRQOL to explore longitudinal trends in HRQOL throughout the disease journey. Methods: An observational, prospective database encompassing all newly-diagnosed, pathology-confirmed adult HGG patients treated in Hamilton, Ontario was developed. Demographic and clinical data was broadly collected. HRQOL questionnaires including the FACT-Br and EORTC-QLQ BN20 were administered at various timepoints up to 1 year following surgery. Longitudinal changes in HRQOL were analyzed using linear mixed-effects models. All analyses were completed using IBM SPSS Statistics for MacIntosh (Version 29.0, IBM Corp 2023), with a significance level of p &lt;0.05. Results: The total number of participants in the cohort was n=65. Survey response rates ranged from 45%-100% for each follow-up timepoint. Linear mixed-effects modelling demonstrated a significant influence of time on EORTC-QLQ BN-20 (p&lt;0.001). Estimated marginal mean scores increased from 23.1 at baseline to 47.2 at 12 months, indicating worsening HRQOL at 12 months. FACT-Br total scores showed no significant difference over time (p = 0.754). Regarding the HRQOL subscales, there was a significant influence of time on social well-being (p=0.032), though not in physical, emotional, or functional subscales (all p&gt;0.10). Conclusion: This thesis provides information regarding longitudinal trends in HRQOL in HGG. Namely, we found that during treatment stages, HRQOL remains relatively stable, with a slight decrease in social functioning. Immediately following the treatment stages, HRQOL may slightly improve before declining towards disease progression and/or end of life. Limitations of this study include the small sample size (particularly at later time points), possible bias of results towards better-functioning individuals, and poor representation of end-of-life due to patient withdrawal at this stage. HRQOL research in HGG is a challenging endeavour which requires substantial multidisciplinary support to develop meaningful results. Nonetheless, it is a meaningful and important topic that requires greater attention to encourage multidisciplinary and holistic support of HGG patients throughout their illness journey.","abstract_has_math":false,"creators":["Hart, Shannon"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Health Research Methodology","school":null,"contributors":[],"advisors":["Sharma, Sunjay","Omar, Abdelsimar II","Whitlock, Richard"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:38:14Z","subjects":["glioma","quality of life","glioblastoma","brain tumour"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/2283"],"render_values":[{"text":"https://doi.org/10.71548/2283","href":"https://doi.org/10.71548/2283","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33499","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33499","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33499","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Sharma, Sunjay","Omar, Abdelsimar II","Whitlock, Richard"]},{"key":"dc:contributor.department","label":"Department","values":["Health Research Methodology"]},{"key":"dc:creator","label":"Author","values":["Hart, Shannon"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-08-25T18:51:50Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["glioma","quality of life","glioblastoma","brain tumour"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33499","https://doi.org/10.71548/2283"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Introduction: Intracranial high-grade glioma (HGG) is an aggressive intra-axial brain malignancy with unfortunately poor prognosis. Increasing survival is a major focus of current research, with much less emphasis on the quality of life that patients have remaining. The existing data focuses on single moments in the disease process, primarily assessing the impact of one treatment factor on health-related quality of life (HRQOL). Many studies do not use direct, validated measures of HRQOL specific to patients with HGG. The objective of this study is to create a comprehensive database of HGG patients including validated, disease-specific measures of HRQOL to explore longitudinal trends in HRQOL throughout the disease journey. Methods: An observational, prospective database encompassing all newly-diagnosed, pathology-confirmed adult HGG patients treated in Hamilton, Ontario was developed. Demographic and clinical data was broadly collected. HRQOL questionnaires including the FACT-Br and EORTC-QLQ BN20 were administered at various timepoints up to 1 year following surgery. Longitudinal changes in HRQOL were analyzed using linear mixed-effects models. All analyses were completed using IBM SPSS Statistics for MacIntosh (Version 29.0, IBM Corp 2023), with a significance level of p <0.05. Results: The total number of participants in the cohort was n=65. Survey response rates ranged from 45%-100% for each follow-up timepoint. Linear mixed-effects modelling demonstrated a significant influence of time on EORTC-QLQ BN-20 (p<0.001). Estimated marginal mean scores increased from 23.1 at baseline to 47.2 at 12 months, indicating worsening HRQOL at 12 months. FACT-Br total scores showed no significant difference over time (p = 0.754). Regarding the HRQOL subscales, there was a significant influence of time on social well-being (p=0.032), though not in physical, emotional, or functional subscales (all p>0.10). Conclusion: This thesis provides information regarding longitudinal trends in HRQOL in HGG. Namely, we found that during treatment stages, HRQOL remains relatively stable, with a slight decrease in social functioning. Immediately following the treatment stages, HRQOL may slightly improve before declining towards disease progression and/or end of life. Limitations of this study include the small sample size (particularly at later time points), possible bias of results towards better-functioning individuals, and poor representation of end-of-life due to patient withdrawal at this stage. HRQOL research in HGG is a challenging endeavour which requires substantial multidisciplinary support to develop meaningful results. Nonetheless, it is a meaningful and important topic that requires greater attention to encourage multidisciplinary and holistic support of HGG patients throughout their illness journey."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Bachelor of Science (BSc)"]},{"key":"dc:description.sponsorship","label":"Dc Description Sponsorship","values":["Ministry of Health Canadian Institutes of Health Research McMaster Surgical Associates"]},{"key":"dc:title","label":"Title","values":["Longitudinal Health-Related Quality of Life in Adult High Grade Glioma Patients: A Single Centre Observational Database"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Sharma, Sunjay","Omar, Abdelsimar II","Whitlock, Richard"],"dc:contributor.department":["Health Research Methodology"],"dc:creator":["Hart, Shannon"],"dc:date.accessioned":["2026-08-25T18:51:50Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Introduction: Intracranial high-grade glioma (HGG) is an aggressive intra-axial brain malignancy with unfortunately poor prognosis. Increasing survival is a major focus of current research, with much less emphasis on the quality of life that patients have remaining. The existing data focuses on single moments in the disease process, primarily assessing the impact of one treatment factor on health-related quality of life (HRQOL). Many studies do not use direct, validated measures of HRQOL specific to patients with HGG. The objective of this study is to create a comprehensive database of HGG patients including validated, disease-specific measures of HRQOL to explore longitudinal trends in HRQOL throughout the disease journey. Methods: An observational, prospective database encompassing all newly-diagnosed, pathology-confirmed adult HGG patients treated in Hamilton, Ontario was developed. Demographic and clinical data was broadly collected. HRQOL questionnaires including the FACT-Br and EORTC-QLQ BN20 were administered at various timepoints up to 1 year following surgery. Longitudinal changes in HRQOL were analyzed using linear mixed-effects models. All analyses were completed using IBM SPSS Statistics for MacIntosh (Version 29.0, IBM Corp 2023), with a significance level of p <0.05. Results: The total number of participants in the cohort was n=65. Survey response rates ranged from 45%-100% for each follow-up timepoint. Linear mixed-effects modelling demonstrated a significant influence of time on EORTC-QLQ BN-20 (p<0.001). Estimated marginal mean scores increased from 23.1 at baseline to 47.2 at 12 months, indicating worsening HRQOL at 12 months. FACT-Br total scores showed no significant difference over time (p = 0.754). Regarding the HRQOL subscales, there was a significant influence of time on social well-being (p=0.032), though not in physical, emotional, or functional subscales (all p>0.10). Conclusion: This thesis provides information regarding longitudinal trends in HRQOL in HGG. Namely, we found that during treatment stages, HRQOL remains relatively stable, with a slight decrease in social functioning. Immediately following the treatment stages, HRQOL may slightly improve before declining towards disease progression and/or end of life. Limitations of this study include the small sample size (particularly at later time points), possible bias of results towards better-functioning individuals, and poor representation of end-of-life due to patient withdrawal at this stage. HRQOL research in HGG is a challenging endeavour which requires substantial multidisciplinary support to develop meaningful results. Nonetheless, it is a meaningful and important topic that requires greater attention to encourage multidisciplinary and holistic support of HGG patients throughout their illness journey."],"dc:description.degree":["Bachelor of Science (BSc)"],"dc:description.sponsorship":["Ministry of Health Canadian Institutes of Health Research McMaster Surgical Associates"],"dc:identifier.uri":["https://hdl.handle.net/11375/33499","https://doi.org/10.71548/2283"],"dc:language.iso":["en"],"dc:subject":["glioma","quality of life","glioblastoma","brain tumour"],"dc:title":["Longitudinal Health-Related Quality of Life in Adult High Grade Glioma Patients: A Single Centre Observational Database"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:38:14Z"}